Clinical Trials Browser

Phase 1 × OTHER × olaparib × Clear all

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT02787642 2026-02-25

RADIOSARP

Phase 1 Completed

41 enrolled 15 charts

Sarcoma

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Phase 1 Recruiting

BRCA1 Mutation

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT06856499 2026-01-09

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

Fallopian Tube Neoplasms

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03955640 2025-12-22

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Phase 1 Terminated

Breast Neoplasms

NCT01858168 2025-12-19

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Phase 1 Completed

Rhabdomyosarcoma, Sarcoma, Ewing

NCT04550104 2025-12-19

CONCORDE

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03109080 2025-11-24

RadioPARP

Phase 1 Completed

Radiation Injuries, Triple Negative Breast Neoplasms

NCT05900895 2025-11-20

PHOEBE

Phase 1 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Phase 1 Completed

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms

NCT06130254 2025-10-14

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Recruiting

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT06488378 2025-08-22

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT07090369 2025-07-29

LumOnate

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT05870423 2025-06-05

PRRT-PARPi

Phase 1 Recruiting

Neuroendocrine Tumors

NCT03874884 2025-05-14

LuPARP

Phase 1 Active not recruiting

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03532880 2025-02-07

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Phase 1 Completed

Small Cell Lung Carcinoma

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Phase 1 Active not recruiting

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02338622 2024-09-26

ComPAKT

Phase 1 Completed

Advanced Cancer

NCT02308072 2024-05-08

ORCA-2

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02229656 2023-11-07

Olaparib and Radiotherapy in Head and Neck Cancer

Phase 1 Unknown

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms

NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT02227082 2021-08-04

Olaparib and Radiotherapy in Inoperable Breast Cancer

Phase 1 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT03544125 2020-11-20

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT02121990 2020-08-21

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02686008 2020-01-13

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03575078 2019-09-25

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Phase 1 Withdrawn

Lymphoma

NCT01758731 2019-09-23

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

Phase 1 Completed

17 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Smoking

NCT02324998 2019-08-29

CaNCaP03

Phase 1 Completed

Prostatic Neoplasms

NCT02418624 2019-01-16

REVIVAL

Phase 1 Completed

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT01390571 2018-02-05

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01296763 2016-03-22

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Phase 1 Completed

18 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01460888 2013-08-19

ROCOCO

Phase 1 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT01491139 2012-05-30

ORCA

Phase 1 Withdrawn

Carcinoma, Squamous Cell